Featured Articles

  1. An Updated View of The Federal Segment: DHA Formulary Management 2/25/2025

    Part two of a three-part series aimed at helping drug and device manufacturers better navigate and understand the Veterans Affairs and Department of Defense health systems.

  2. FCPA Enforcement Paused At DOJ, But Biopharma Shouldn't Pause Compliance 2/21/2025

    Criminal enforcement of the Foreign Corrupt Practices Act was paused on February 10 by a Trump administration executive order. That doesn't mean biopharmaceutical companies can backslide on compliance in global markets.

  3. A Guide To Successful Product Launches For Small And Midsized Biotechs 2/19/2025

    Abhijit Naravane, a partner at PA Consulting, outlines strategies to help biopharma operations leaders successfully navigate the complexities of a product launch.

     

  4. Tax Planning For Life Sciences Amid Shifting Policies 2/11/2025

    Tax policy shifts can directly affect corporate structure decisions, overall business strategy, and the ability to allocate resources effectively. In 2025, staying ahead of these changes will be vital, writes life sciences tax expert Richard Weiner.

  5. The Spark Of Change In Healthcare's 2024 Investment Ecosystem 2/6/2025

    Strong private equity investment and strategic M&A in 2024, and a shift toward clinical-stage companies and asset-driven strategies, have set the healthcare and biotech industries on a positive trajectory for 2025, writes Joseph Pategou.

  6. How Pharma Can Best Manage Third-Party Risk 2/4/2025

    Experts at Crowe Life Sciences offer tips for effectively managing risk associated with third parties such as clinics, retail pharmacies, health information system providers, and independent research organizations.

  7. Rethinking Global-To-Local Pricing And Market Access For Pharmaceuticals 1/31/2025

    Simon-Kucher's industry study reveals barriers and success factors for improving global pricing and marketing access strategies, from core markets to the local affiliate level in non-core markets.

  8. Biopharma R&D Faces Productivity And Attrition Challenges In 2025 1/29/2025

    Evaluate VP of Thought Leadership Daniel Chancellor discusses trends for 2025 as the surge in R&D, coupled with rapidly evolving industry dynamics, presents a productivity and attrition challenge for the industry.

  9. Court Ruling Alters the Calculus for Orange Book Patent Listings 1/23/2025

    Recent court rulings have changed the way branded and generic drug manufacturers should think about patent listings in the FDA Orange Book. Hatch-Waxman experts at Polsinelli detail the changes and implications, and make predictions about what comes next.

  10. Unlocking The Potential Of AI In Pharma: The Power Of Data Systems 1/10/2025

    Clean, humanized data and data systems are the crucial fuel for engines driving new AI capabilities and uses across the biopharmaceutical industry. Data integrity, accessibility, and ethical use of data are prerequisites for turning data systems and AI into trusted allies.